Detalles de la búsqueda
1.
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 388(21): 1966-1980, 2023 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37224198
2.
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Clin Gastroenterol Hepatol
; 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38492903
3.
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Clin Gastroenterol Hepatol
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38723981
4.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Clin Gastroenterol Hepatol
; 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38492904
5.
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis.
Gastroenterology
; 164(7): 1180-1188.e2, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871598
6.
Gut Microbiome Composition Is Associated With Future Onset of Crohn's Disease in Healthy First-Degree Relatives.
Gastroenterology
; 165(3): 670-681, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37263307
7.
Environmental Factors Associated with Risk of Crohn's Disease Development in the CCC-GEM Project.
Clin Gastroenterol Hepatol
; 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38759825
8.
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol
; 2024 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38095692
9.
Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis.
Am J Gastroenterol
; 2024 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38299598
10.
A practical guide to combination advanced therapy in inflammatory bowel disease.
Curr Opin Gastroenterol
; 40(4): 251-257, 2024 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38662117
11.
Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study.
Dig Dis Sci
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700629
12.
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis.
Gut
; 72(8): 1462-1471, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788016
13.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet
; 399(10342): 2200-2211, 2022 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691323
14.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
15.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
16.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644166
17.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35134323
18.
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Clin Gastroenterol Hepatol
; 21(9): 2347-2358.e6, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36464141
19.
Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity.
Clin Gastroenterol Hepatol
; 2023 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38056798
20.
Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation.
Gastroenterology
; 163(3): 685-698, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35643175